Keyword: Foundation Medicine
CMS has given the final go-ahead for coverage of Foundation Medicine’s pan-cancer genomic test that was approved by the FDA late last year.
F1CDx is an NGS-based test to detect alterations in 324 genes relevant to a range of solid tumors.
Foundation Medicine announced new clinical markers to its FoundationOne and FoundationOne Heme products. Using FoundationOne and FoundationOne Heme assays, clinicians can now glean insights from TMB and MSI.
Foundation Medicine’s FoundationOne tech has been accepted for Parallel Review by both the U.S. FDA and the Centers for Medicare and Medicaid Services.